Overview of post marketing aggregate reports and global regulatory requirements
Abstract
Keywords
Full Text:
PDFReferences
World Health Organization. Pharmacovigilance: Ensuring the Safe Use of Medicines - WHO Policy Perspectives on Medicines, 2004. Available at http://apps.who.int/medicinedocs/en/d/Js6164e/. Accessed on 17 November 2016.
World Health Organization. Safety of Medicines: A guide to detecting and reporting adverse drug reactions, 2002. Available at http://apps.who.int/ medicinedocs/es/d/Jh2992e/ Accessed on 17 November 2016.
Gagnon S, Gagnon S, Schueler P. Pharmacovigilance and Risk Management. In: Bairu M, Chin R, eds. Global Clinical Trials Playbook. 1st ed. United Kingdom, UK: Elsevier; 2012: 141-160.
The International Council for Harmonisation. Pharmacovigilance: ICH Topic E 2 C (R1) Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs, 1997. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002780.pdf. Accessed on 23 November 2016.
The International Council for Harmonisation. Pharmacovigilance: ICH guideline E2C (R2) on periodic benefit-risk evaluation report (PBRER), 2013. Available at: http://www.ich.org/products/ guidelines/efficacy/article/efficacy-guidelines.html. Accessed on 23 November 2016.
Committee for Human Medicinal Products (CHMP). Guideline on the processing of renewals in the centralized procedure, 2016. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/08/WC500211495. Accessed on 24 November 2016.
The Heads of Medicines Agencies (HMA). Human Medicines: CMDh best practice guide on the processing of renewals in the mutual recognition and decentralised procedures, 2015. Available at http://www.hma.eu/95.html. Accessed on 24 November 2016.
Food and Drug Administration (FDA). Post marketing reporting of adverse drug experiences, Code of Federal Regulations, 21CFR314.80, 2016. Available at https://www.gpo.gov/fdsys/granule/ CFR-2011-title21-vol5/CFR-2011-title21-vol5-sec314-80. Accessed on 06 December 2016.
Food and Drug Administration (FDA). Applications for FDA approval to market a new drug, Code of Federal Regulations, 21CFR314.80, 2016. Available at https://www.gpo.gov/fdsys/granule/CFR-2011-title21-vol5/CFR-2011-title21-vol5-sec314-80. Accessed on 06 December 2016.
Food and Drug Administration (FDA). Reporting of Adverse Experiences, Code of Federal Regulations, 21CFR314.80, 2016. Available at https://www.gpo. gov/fdsys/granule/CFR-2011-title21-vol5/CFR-2011-title21-vol5-sec314-80. Accessed on 06 December 2016.
Food and Drug Administration (FDA). Providing post marketing periodic safety reports in the ICH E2C(R2) format (Periodic Benefit-Risk Evaluation Report) Guidance for Industry, 2016. Available at https://www.fda.gov/downloads/drugs/guidances/ucm346564. Accessed on 15 December 2016.
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VII - Periodic safety update report (Rev 1), 2013. Available at http://www.ema.europa.eu/ema/index .jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp. Accessed on 10 January 2017.
Health Canada. Drugs & Health Products: Guidance documents on Product Vigilance, 2013. Available on: http://www.hc-sc.gc.ca/dhpmps/prodpharma/ applic- demande/guide-ld/vigilance/index-eng.php; Accessed on 14 December 2016.
Therapeutic Goods Administration. Australian requirements and recommendations for pharmacovigilance responsibilities of sponsors of medicines, 2014. Available on https://www.tga. gov.au/publication/australian-pharmacovigilance-requirements-and-recommendations-medicine-sponsors. Accessed on 18 January 2017.
Harvey B. Periodic Safety Update Reports - Some commonly asked questions, Association of Regulatory and Clinical Scientists (ARCS) Workshop, 2015. Available at: https://www.tga.gov. au/presentation-periodic-safety-update-reports-some-commonly-asked-questions. Accessed on 24 January 2017.
Health Sciences Authority, Singapore. Guidance for Industry – Post-marketing Vigilance Requirements for Medicinal Products, 2015. Available at: http://www.hsa.gov.sg/content/dam/HSA/HPRG/Safety_Alerts_Product_Recalls_Enforcement/Guidance%20for%20Industry_Post-marketing%20Vigilance%20Req%20for%20Med%20Prod_June%202015. Accessed on 24 January 2017.
Central Drugs Standard Control Organization, India. Schedule “Y”, clause 4; Drug and Cosmetics Rules 1945, 2016. Available at: http://cdsco.nic.in/html/ D&C_Rules_Schedule_Y.pdf. Accessed on 12 December 2016.